

Anxiolytic-like Effects of Dichloromethane Extracts of Valerian (DEV) in Adult Male Wistar Rats

Hadjikhani R.

Abstract—Anxiety is a common disorder that attacks many people in society and often accompanied by physiological sensations such as tachycardia, chest pain, shortness of breath, insensitivity and etc. The purpose of this study is to characterize the putative anxiolytic-like effects of DEV (dichloromethane extracts of valerian) using the elevated plus maze (EPM) in rats. DEV was dissolved in DMSO and orally administered at different doses to adult male wistar rats, 0.5, 1.5 and 3 hours before behavioral evaluation in an EPM respectively. Control rats were treated with an equal volume of DMSO. Single treatment of DEV (at 0.1, 0.2, 0.3, and 0.4 g/kg) significantly increased time-spent and arm entries into open arms of EPM versus control groups ($p < 0.05$). However, no changes in the locomotor activity occurred. This result suggests that DEV might prove to be an effective anxiolytic agent.

Keywords—Anxiety, Dichloromethane extracts, Valerian, Rat

I. INTRODUCTION

ANXIETY and depression are the most frequent mental disorders. More than 20% of adult population suffer from this condition at some time during their life [1]. Anxiety has become a very important area of research interest in psychopharmacology in this decade. This increased interest is the result of a rapid growth of scientific studies and the discovery of new drugs that alter anxiety in animal models [2]. Benzodiazepines have been the most widely used anxiolytics in general practice for many years [3] and are relatively safe drugs for short term treatment of anxiety despite their dependence potential and side effects [3], [4]. Nevertheless, there is considerable interest in development of new anxiolytics. New synthesized compounds as well as drugs derived from traditional herbs may have a possible therapeutic relevance in the treatment of anxiety [3], [5], [6].

Valerian (*Valeriana Officinalis L.*) is an herb that has long been used as a tranquilizer and sleep inducer [7]. Multiple substance in the valerian extracts are held responsible for their effects and most important among them are the terpenoid esters named valepotriates, their decomposition products, the

baldirinal and various components of the essential oil, in particular, the valerenic acid derivatives. The valepotriates exhibit an activity between sedation and tranquilization and are called aequilans, which have a specific dampening effect on the central nervous system [4], [7], [8].

In the present study, effects of DEV administered and their possible roles in the modulation of anxiety behaviors using elevated plus-maze in rats have been investigated.

II. MATERIAL AND METHODS

A. Animals

Male Wistar rats from Pasteur Institute (Iran), weighing 180–230 g at the time treatment, were used. The animals were housed four per cage in a room with a 12:12 h light / dark cycle (lights on 07:00 hours) and controlled temperature ($23 \pm 1^\circ\text{C}$). They had access to food and water ad libitum and were allowed to adapt to the laboratory conditions for at least 1 week before treatment. Rats were handled about 3 minutes each day prior to behavioral testing. All experiments were performed between 12:00 and 15:00 hours and each rat was tested only once.

B. Elevated Plus-Maze (EPM)

This wooden, plus-shaped apparatus was elevated to a height of 50 cm, and consisted of two 50×10 cm open arms, and two $50 \times 10 \times 50$ cm enclosed arms, each with an open roof. The maze was in the center of a quiet and dimly lit room. The rats' behaviour was observed using a mirror that was suspended at an angle above the maze. Behavioural data were collected by a "blind" observer who quietly sat 1 meter behind one of the closed arms of the maze. Five minutes following their respective drug treatment, rats were placed individually in the center of the plus-maze, facing one of the closed arms. The observer measured (1) time spent in the open arms, (2) time spent in the closed arms, (3) number of entries into the open arms, and (4) number of entries into the closed arms during the 5-min test period. An entry was defined as all four paws in the arm. The maze was cleaned with distilled water after each rat was tested. For the purpose of analysis (Degroot et al., 2001; Pellow, 1986; Pellow et al., 1985), open-arm activity was quantified as the amount of time that the rat spent in the open arms relative to the total amount of time spent in any arm ($\text{open}/\text{total} \times 100$), and the number of entries into the open arms was quantified relative to the total number of

H. R. Department of Biology, Islamic Azad University-Karaj branch, Karaj, IRAN (phone: +98261-4418143-6 Fax: +982614477205 e-mail: hajikhani@kiauo.ac.ir).

entries into any arm ($\text{open}/\text{total} \times 100$). The total number of arms entered, as well as the total number of closed arms entered were used as indexes of general activity [9; 10; 11]

C. Preparation of Extract

Roots of valerian were collected from regional farms in Esfahan province of Iran and Taxonomic identification was performed by dr. Ghahremani Nejad is deposited in herbarium of Tarbiyat Moallem university of Tehran. Roots were dried under dark conditions at room temperature for 2 weeks and then grounded in an electrical mill to obtain particle lesser than 5 mm. 20 g of powdered plant material was homogenized and extracted with 300 mL dichloromethane for 24 hours and then filtered. The filtrate was evaporated to dryness under vacuum at 30°C. The residue was weighed and dissolved in DMSO and used for treatment [7; 12; 13].

DEV was dissolved in 1 mL DMSO and orally administrated (gavage) at doses of 0.025, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5 and 1 g/kg of body weight. Each dose administrated to 3 groups (N=8) of rats, 0.5, 1.5 and 3 hours before behavioral evaluation in an EPM respectively. Control rats were treated with an equal volume of DMSO.

D. Statistical Analysis

Since data displayed normality of distribution and homogeneity of variance, one-way ANOVA was used for comparison between the effects of different doses of drugs with vehicle.

III. RESULTS

Fig.1 shows the effect of DEV (0.1 g/kg), 0.5, 1.5 and 3 hours after oral administration in the elevated plus-maze in rats. One-way ANOVA revealed that DEV increased time spent in the open arms (%OAT) (0.5 and 1.5 hours after oral administration) and number of entries into the open arms (%OAE) at the doses of 0.1 g/kg, indicating the induction of anxiolytic response by DEV. No change in the locomotor activity was observed.

Oral administration of DEV (0.2 g/kg) produced clear anxiolytic effects in the elevated plus-maze. Rats treated with DEV (0.2 g/kg) showed a significantly greater percentage of %OAT and %OAE than control rats. No change in the locomotor activity was observed (fig. 2)

Fig.3 shows the anxiolytic-like effect of DEV (0.3 g/kg) in the elevated plus-maze in rats (0.5, 1.5 and 3 hours after oral administration). One-way ANOVA revealed that DEV increased time spent in the open arms (%OAT) and number of entries into the open arms (%OAE) at the dose of 0.3 g/kg, indicating the induction of anxiolytic response by DEV. No change in the locomotor activity was observed.

Fig.4 shows the behavioral effect of DEV (0.4 g/kg) in the elevated plus-maze in rats (0.5, 1.5 and 3 hours after oral administration). One-way ANOVA revealed that DEV at dose of 0.4 g/kg have no significant effect on time spent in the open arms (%OAT), This dose increase number of entries into the open arms (%OAE) 1.5 hours after oral administration. No change in the locomotor activity was observed.




Fig. 1 Effects of DEV, 0.5, 1.5 and 3 hours after oral administration in the elevated plus-maze. Rats were treated with either DMSO (1 ml/rat) or with DEV (0.1 g/kg). Each bar is mean \pm S.E.M. %Open Arm Time (a), %Open Arm Entries (b) or locomotor activity (c). N = 8. *P < 0.05, when compared to the DMSO treated control rats.




Fig. 2 Effects of DEV at dose of 0.2 g/kg (0.5, 1.5 and 3 hours after oral administration) in the elevated plus-maze. Rats were treated with either DMSO (1 ml/rat) or with DEV (0.2 g /kg). Each bar is mean \pm S.E.M. %Open Arm Time (a), %Open Arm Entries (b) or locomotor activity (c). $N = 8$. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ when compared to the DMSO treated control rats.




Fig. 3 Effects of DEV at dose of 0.3 g/kg (0.5, 1.5 and 3 hours after oral administration) in the elevated plus-maze. Rats were treated with either DMSO (1 ml/rat) or with DEV (0.3 g /kg). Each bar is mean \pm S.E.M. %Open Arm Time (a), %Open Arm Entries (b) or locomotor activity (c). $N = 8$. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ when compared to the DMSO treated control rats.




Fig. 4 Effects of DEV at dose of 0.4 g/kg (0.5, 1.5 and 3 hours after oral administration) in the elevated plus-maze. Rats were treated with either DMSO (1 ml/rat) or with DEV (0.4 g /kg). Each bar is mean \pm S.E.M. %Open Arm Time (a), %Open Arm Entries (b) or locomotor activity (c). $N = 8$. * $P < 0.05$ when compared to the DMSO treated control rats.

IV. DISCUSSION

Valerian is one of the most commonly used herbal medicines in Iran that used for the treatment of tachycardia,

anxiety and insomnia.

In the present study, the effects of valepotriates extracted from valerian on anxiety behavior in the elevated plus-maze have been investigated.

The elevated plus-maze is one of the many tests for the identification of anxiolytic or anxiogenic effect of a drug in rodents [14]. However, there may be other methods such as the Vogel conflict test [15].

The result of this research shows that DEV (0.1, 0.2 and 0.3 g/kg) increased %OAT (% Open Arm Times) and %OAE (% Open Arm Entries), without locomotor impairment in the elevated plus maze, indicating the induction of anxiolytic-like response by Valerian. Previous studies show that valerian concludes tranquilizing effects and can treat sleep disorders in human [16], [17]. There is not more published information about physiological mechanism of DEV anxiolytic effects.

However, pervious studies show that Valerian or its constituents can induce their effects by interacting with central GABAergic system [18], [19]. Chun-Su Yuan and colleagues suggest that the pharmacological effects of valerian extract and valerianic acid are mediated through modulation of GABAA receptor function [19]. It has been shown that valerian extract, aqueous or hydroalcoholic, contained GABA and other amino acids that can displace labeled muscimol [18], [20], suggesting that specific constituents of valerian extract can directly bind to GABAA receptors [21], [22]. Valerian extracts can also be responsible for the stimulated release and reuptake of GABA[21]. Aqueous extract of valerian inhibited the uptake and stimulated the release of [3H]GABA, either in the absence or in the presence of K⁺ depolarization. It is concluded that valerian extract releases [3H]GABA by reversal of the GABA carrier [22]. Derivatives of valerianic acid can also inhibit the local catabolism of GABA by inhibition of the enzyme GABAse, which can also increase GABA concentration [23]. The γ -aminobutyric acid (GABA) is the main inhibitory neurotransmitter, which acts through different receptor sites, termed $GABAA_A$, $GABAB_B$ and $GABAC_C$ [24], [25]. The anxiolytic role of GABAergic system and $GABAA_A$ receptors in the limbic system has been well established [26]-[28].

V. CONCLUSION

The results show that DEV have anxiolytic-like effects. Therefore after complementary experiments, it can be used as treatment to anxiety.

REFERENCES

- [1] S. Mora, R. Millan, H. Lungenstrass, G. Diaz-Veliz, J.A. Moran, M. Herrera-Ruiz, and J. Tortoriello, The hydroalcoholic extract of *Salvia elegans* induces anxiolytic- and antidepressant-like effects in rats. *J Ethnopharmacol* 106 (2006) 76-81.
- [2] W.H. Peng, M.T. Hsieh, Y.S. Lee, Y.C. Lin, and J. Liao, Anxiolytic effect of seed of *Ziziphus jujuba* in mouse models of anxiety. *J Ethnopharmacol* 72 (2000) 435-41.
- [3] A. Rex, E. Morgenstern, and H. Fink, Anxiolytic-like effects of kava-kava in the elevated plus maze test—a comparison with diazepam. *Prog Neuropsychopharmacol Biol Psychiatry* 26 (2002) 855-60.
- [4] F. Donath, S. Quispe, K. Diefenbach, A. Maurer, I. Fietze, and I. Roots, Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. *Pharmacopsychiatry* 33 (2000) 47-53.

- [5] B.R. Ballinger, New drugs. Hypnotics and anxiolytics. *Bmj* 300 (1990) 456-8.
- [6] G. Beaubrun, and G.E. Gray, A review of herbal medicines for psychiatric disorders. *Psychiatr Serv* 51 (2000) 1130-4.
- [7] W. Hui-lian, Z. Dong-fang, L. Zhao-feng, L. Yang, L. Qian-rong, and W. Yu-zhen, In vitro study on the genotoxicity of dichloromethane extracts of valerian (DEV) in human endothelial ECV304 cells and the effect of vitamins E and C in attenuating the DEV-induced DNA damages. *Toxicol Appl Pharmacol* 188 (2003) 36-41.
- [8] H. Schulz, C. Stolz, and J. Muller, The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. *Pharmacopsychiatry* 27 (1994) 147-51.
- [9] A. Degroot, S. Kashluba, and D. Treit, Septal GABAergic and hippocampal cholinergic systems modulate anxiety in the plus-maze and shock-probe tests. *Pharmacol Biochem Behav* 69 (2001) 391-9.
- [10] S. Pellow, Anxiolytic and anxiogenic drug effects in a novel test of anxiety: are exploratory models of anxiety in rodents valid? *Methods Find Exp Clin Pharmacol* 8 (1986) 557-65.
- [11] R.J. Rodgers, and N.J. Johnson, Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. *Pharmacol Biochem Behav* 52 (1995) 297-303.
- [12] A. Backlund, and T. Moritz, Phylogenetic implications of an expanded valepotriate distribution in the Valerianaceae, Elsevier, 1998, pp. 309-335.
- [13] A. Herrera-Arellano, G. Luna-Villegas, M.L. Cuevas-Urriostegui, L. Alvarez, G. Vargas-Pineda, A. Zamilpa-Alvarez, and J. Tortoriello, Polysomnographic evaluation of the hypnotic effect of Valeriana edulis standardized extract in patients suffering from insomnia, 2001, pp. 695-9.
- [14] S. Pellow, P. Chopin, S.E. File, and M. Briley, Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. *J Neurosci Methods* 14 (1985) 149-67.
- [15] T. Umezu, Effects of psychoactive drugs in the Vogel conflict test in mice. *Jpn J Pharmacol* 80 (1999) 111-8.
- [16] G. Balderer, and A.A. Borbely, Effect of valerian on human sleep. *Psychopharmacology (Berl)* 87 (1985) 406-9.
- [17] P.J. Houghton, The scientific basis for the reputed activity of Valerian. *J Pharm Pharmacol* 51 (1999) 505-12.
- [18] K. Low, F. Crestani, R. Keist, D. Benke, I. Brunig, J.A. Benson, J.M. Fritschy, T. Rulicke, H. Bluethmann, H. Mohler, and U. Rudolph, Molecular and neuronal substrate for the selective attenuation of anxiety. *Science* 290 (2000) 131-4.
- [19] C.S. Yuan, S. Mehendale, Y. Xiao, H.H. Aung, J.T. Xie, and M.K. Ang-Lee, The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. *Anesth Analg* 98 (2004) 353-8, table of contents.
- [20] C. Cavadas, I. Araujo, M.D. Cotrim, T. Amaral, A.P. Cunha, T. Macedo, and C.F. Ribeiro, In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brain. *Arzneimittelforschung* 45 (1995) 753-5.
- [21] M.S. Santos, F. Ferreira, A.P. Cunha, A.P. Carvalho, and T. Macedo, An aqueous extract of valerian influences the transport of GABA in synaptosomes. *Planta Med* 60 (1994) 278-9.
- [22] M.S. Santos, F. Ferreira, A.P. Cunha, A.P. Carvalho, C.F. Ribeiro, and T. Macedo, Synaptosomal GABA release as influenced by valerian root extract--involvement of the GABA carrier. *Arch Int Pharmacodyn Ther* 327 (1994) 220-31.
- [23] E. Riedel, R. Hansel, and G. Ehrke, [Inhibition of gamma-Aminobutyric Acid Catabolism by Valerenic Acid Derivatives.]. *Planta Med* 46 (1982) 219-220.
- [24] M. Chebib, and G.A. Johnston, The 'ABC' of GABA receptors: a brief review. *Clin Exp Pharmacol Physiol* 26 (1999) 937-40.
- [25] R. Oksztel, H. Car, and K. Wisniewski, Muscimol changes hypoxia-induced impairment of behavior in rats. *Pol J Pharmacol* 54 (2002) 423-31.
- [26] A. Plaznik, W. Kostowski, and R. Stefanski, Limbic mechanisms of anxiolytics acting on 5-HT receptors. *Pol J Pharmacol* 46 (1994) 473-7.
- [27] H. Sienkiewicz-Jarosz, J. Szyndler, A.I. Czlonkowska, M. Siemiakowski, P. Maciejak, A. Wislowska, M. Zienowicz, M. Lehner, D. Turzynska, A. Bidzinski, and A. Plaznik, Rat behavior in two models of anxiety and brain [3H]muscimol binding: pharmacological, correlation, and multifactor analysis. *Behav Brain Res* 145 (2003) 17-22.
- [28] R. Stefanski, W. Palejko, A. Bidzinski, W. Kostowski, and A. Plaznik, Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of midazolam and 5-HT1A receptor agonists. *Neuropharmacology* 32 (1993) 977-85.